» Articles » PMID: 27449671

Factors Associated with 10 Years of Continuous Viral Load Suppression on HAART

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2016 Jul 25
PMID 27449671
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The principal goal of HAART is sustained viral load (VL) suppression resulting in immune reconstitution and improved HIV outcomes. We studied the factors associated with 10 years of continuous VL suppression on HAART in the US Military HIV Natural History Study.

Methods: Participants with continuous VL suppression (CS, n = 149) were compared to those who did not have continuous viral load suppression (NCS, n = 127) for ≥10 years on HAART. Factors associated with >10 years of VL suppression were evaluated by multivariate logistic regression. Additionally, association between CS and CD4 reconstitution was analyzed with a mixed effects model.

Results: Compared to NCS participants, a lower proportion of CS participants started HAART in the early HAART era (66 vs 90 %, for years 1996-1999; p < 0.001) and had less antiretroviral use prior to HAART (37 vs 83 %; p < 0.001). At initial HAART, the median CD4 cell count was higher and VL was lower for CS compared to NCS participants (375 cells/uL [256, 499] vs 261 cells/uL [146, 400]; p < 0.001 and 4.4 log10 copies/mL [3.5, 4.9] vs 4.5 log10 copies/mL [3.8, 5.0]; p = 0.048, respectively). New AIDS events were lower during HAART (5 vs 13 %; p = 0.032) and post-HAART CD4 trajectories were greater for the CS compared to NCS group. Factors negatively associated with ≥10 years of VL suppression included log10 VL at first HAART (OR 0.61, 95 % CI 0.4, 0.92; p = 0.020) and antiretroviral use prior to HAART (OR 0.16, 95 % CI 0.06, 0.38; p < .001).

Conclusions: Sustained VL suppression is a key to long-term health in HIV-infected patients, as demonstrated by the lower proportion of AIDS events observed 10 years after HAART initiation. The current use of more potent and well-tolerated regimens may mitigate the negative factors of pre-HAART VL and prior ARV use encountered by treatment initiated in the early HAART era.

Citing Articles

Evaluation of Treatment Outcomes Among Individuals on Highly Active Antiretroviral Therapy in KwaZulu-Natal, South Africa.

Muzumbukilwa T, Manimani R, Mushebenge A, Vagiri R, Nlooto M AIDS Res Treat. 2024; 2024:8834740.

PMID: 39691492 PMC: 11651757. DOI: 10.1155/arat/8834740.


Beliefs about antiretroviral therapy and their association with adherence in young people living with perinatal HIV in England: a cross-sectional analysis.

White I, Judd A, Castro H, Chappell E AIDS Care. 2024; :1-17.

PMID: 38269578 PMC: 7617179. DOI: 10.1080/09540121.2023.2300984.


Clinical factors and outcomes associated with immune non-response among virally suppressed adults with HIV from Africa and the United States.

Noiman A, Esber A, Wang X, Bahemana E, Adamu Y, Iroezindu M Sci Rep. 2022; 12(1):1196.

PMID: 35075147 PMC: 8786968. DOI: 10.1038/s41598-022-04866-z.


Everything counts - a method to determine viral suppression among people living with HIV using longitudinal data for the HIV care continuum - results of two large, German, multi-center real-life cohort studies over 20 years (1999-2018).

Schmidt D, Kollan C, Stoll M, Hamouda O, Bremer V, Kurth T BMC Public Health. 2021; 21(1):200.

PMID: 33482773 PMC: 7825204. DOI: 10.1186/s12889-020-10088-7.


Annual and durable HIV retention in care and viral suppression among patients of Peter Ho Clinic, 2013-2017.

Mohammed D, Koumoulos L, Martin E, Slim J PLoS One. 2020; 15(12):e0244376.

PMID: 33373385 PMC: 7771864. DOI: 10.1371/journal.pone.0244376.


References
1.
Willis S, Castel A, Ahmed T, Olejemeh C, Frison L, Kharfen M . Linkage, engagement, and viral suppression rates among HIV-infected persons receiving care at medical case management programs in Washington, DC. J Acquir Immune Defic Syndr. 2013; 64 Suppl 1:S33-41. PMC: 3844615. DOI: 10.1097/QAI.0b013e3182a99b67. View

2.
Weintrob A, Grandits G, Agan B, Ganesan A, Landrum M, Crum-Cianflone N . Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009; 52(5):574-80. DOI: 10.1097/QAI.0b013e3181b98537. View

3.
Althoff K, Rebeiro P, Brooks J, Buchacz K, Gebo K, Martin J . Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis. 2014; 58(8):1185-9. PMC: 3967825. DOI: 10.1093/cid/ciu044. View

4.
Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A . Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000; 14(7):761-70. DOI: 10.1097/00002030-200005050-00001. View

5.
Freiberg M, Chang C, Kuller L, Skanderson M, Lowy E, Kraemer K . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8):614-22. PMC: 4766798. DOI: 10.1001/jamainternmed.2013.3728. View